BioSig's CEO On Why The Medtech Company Bought An Antiviral Candidate To Fight Coronavirus: 'This Drug Is Really Far Along'
In February, when the first coronavirus-infected cruise goers came home to the U.S., the biodefense lab in Galveston pulled from its freezer one of five antiviral drug candidates developed by Celgene spinoff Trek Therapeutics.
Its test on COVID-19 patients yielded a 98.6% response rate.